Patents by Inventor Salam Kadhim
Salam Kadhim has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230381205Abstract: Provided herein are methods and compositions comprising a cannabinoid compound for providing neuroprotection and/or stimulating neuritogenesis. The cannabinoid compound can be a compound of Formula (I), wherein R1 is COOH or H, R2 is C3H7 or C5H11, R3 is H or Me, R4 and R5 are Me or (CH2)2CH?C(CH3)2, such as CBGA, a derivative thereof, a prodrug thereof, or combinations thereof, and can be used in the treatment of neurodegenerative diseases, or to promote neurite elongation and/or restore neurite formation in patients in need thereof.Type: ApplicationFiled: October 21, 2021Publication date: November 30, 2023Inventors: Eric HSU, Salam KADHIM, Rishi SOMVANSHI, Ujendra KUMAR
-
Publication number: 20210338629Abstract: Described herein are cannabinoid formulations in combination with phenylalanine for oral administration. Further described herein are methods for orally administering one or more cannabinoids to a subject in need thereof and manufacturing oral formulations as described herein.Type: ApplicationFiled: August 26, 2019Publication date: November 4, 2021Inventors: Freydoun GARABAGI, Nancy E. HARRISON, Salam A. KADHIM, Christopher WAGNER
-
Publication number: 20210236575Abstract: Described herein are cannabinoid formulations in combination with curcumin for oral administration. Further described herein are methods for orally administering one or more cannabinoids to a subject in need thereof and manufacturing oral formulations as described herein.Type: ApplicationFiled: August 26, 2019Publication date: August 5, 2021Inventors: Freydoun GARABAGI, Nancy E. HARRISON, Salam A. KADHIM, Christopher WAGNER, Andrew MCBRIDE, Hardip SAHOTA
-
Publication number: 20210205236Abstract: Described herein are cannabinoid formulations in combination with Boswellia extract for oral administration. Further described herein are methods for orally administering one or more cannabinoids to a subject in need thereof and manufacturing oral formulations as described herein.Type: ApplicationFiled: August 26, 2019Publication date: July 8, 2021Inventors: Freydoun GARABAGI, Nancy E. HARRISON, Salam A. KADHIM, Christopher WAGNER
-
Publication number: 20210196670Abstract: Described herein are cannabinoid formulations in combination with lavender and/or a lavender extract for oral administration. Further described herein are methods for orally administering one or more cannabinoids to a subject in need thereof and manufacturing oral formulations as described herein.Type: ApplicationFiled: August 26, 2019Publication date: July 1, 2021Inventors: Freydoun GARABAGI, Nancy E. HARRISON, Salam A. KADHIM, Christopher WAGNER
-
Patent number: 8551951Abstract: The invention provides pharmaceutical compositions and method for inhibiting growth of prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, or benign prostate hyperplasia (BPH). In one embodiment the pharmaceutical composition includes human rHuPSP94, antigenic portions thereof, and functionally equivalent polypeptides thereof. In another embodiment, the pharmaceutical composition includes a mixture of human rHuPSP94, antigenic portions thereof, and functionally equivalent polypeptides thereof and an anticancer drug which may be administered in an appropriate dosage form, dosage quantity and dosage regimen to a patient suffering from, for example of prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, benign prostate hyperplasia, or (BPH) gastrointestinal cancer.Type: GrantFiled: January 22, 2010Date of Patent: October 8, 2013Assignee: Aenorasis SA Pharmaceuticals and Medical DevicesInventors: Seema Garde, Chandra J. Panchal, Madhulika Baijal-Gupta, Jennifer Fraser, Salam Kadhim
-
Publication number: 20100239653Abstract: The invention provides pharmaceutical compositions and method for inhibiting growth of prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, or benign prostate hyperplasia (BPH). In one embodiment the pharmaceutical composition includes human rHuPSP94, antigenic portions thereof, and functionally equivalent polypeptides thereof. In another embodiment, the pharmaceutical composition includes a mixture of human rHuPSP94, antigenic portions thereof, and functionally equivalent polypeptides thereof and an anticancer drug which may be administered in an appropriate dosage form, dosage quantity and dosage regimen to a patient suffering from, for example of prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, benign prostate hyperplasia, or (BPH) gastrointestinal cancer.Type: ApplicationFiled: January 22, 2010Publication date: September 23, 2010Applicant: Kotinos Pharmaceuticals Inc.Inventors: Seema Garde, Chandra J. Panchal, Madhulika Baijal-Gupta, Jennifer Fraser, Salam Kadhim
-
Patent number: 7655631Abstract: The invention provides pharmaceutical compositions and method for inhibiting growth of prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, or benign prostate hyperplasia (BPH) In one embodiment the pharmaceutical composition includes human rHuPSP94, antigenic portions thereof, and functionally equivalent polypeptides thereof. In another embodiment, the pharmaceutical composition includes a mixture of human rHuPSP94, antigenic portions thereof, and functionally equivalent polypeptides thereof and an anticancer drug which may be administered in an appropriate dosage form, dosage quantity and dosage regimen to a patient suffering from, for example of prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, benign prostate hyperplasia, or (BPH) gastrointestinal cancer.Type: GrantFiled: September 30, 2005Date of Patent: February 2, 2010Assignee: Kotinos Pharmaceuticals Inc.Inventors: Seema Garde, Chandra Panchal, Madhulika Baijal-Gupta, Jennifer Fraser, Salam Kadhim
-
Patent number: 7053058Abstract: The invention provides pharmaceutical compositions and method for inhibiting growth of prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, or benign prostate hyperplasia (BPH). In one embodiment the pharmaceutical composition includes human rHuPSP94, antigenic portions thereof, and functionally equivalent polypeptides thereof. In another embodiment, the pharmaceutical composition includes a mixture of human rHuPSP94, antigenic portions thereof, and functionally equivalent polypeptides thereof and an anticancer drug which may be administered in an appropriate dosage form, dosage quantity and dosage regimen to a patient suffering from, for example of prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, benign prostate hyperplasia, or (BPH) gastrointestinal cancer.Type: GrantFiled: October 15, 2001Date of Patent: May 30, 2006Assignee: Procyon Biopharma Inc.Inventors: Seema Garde, Chandra Panchal, Madhulika Baijal-Gupta, Jennifer Fraser, Salam Kadhim
-
Publication number: 20060105949Abstract: The invention provides pharmaceutical compositions and method for inhibiting growth of prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, or benign prostate hyperplasia (BPH) In one embodiment the pharmaceutical composition includes human rHuPSP94, antigenic portions thereof, and functionally equivalent polypeptides thereof. In another embodiment, the pharmaceutical composition includes a mixture of human rHuPSP94, antigenic portions thereof, and functionally equivalent polypeptides thereof and an anticancer drug which may be administered in an appropriate dosage form, dosage quantity and dosage regimen to a patient suffering from, for example of prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, benign prostate hyperplasia, or (BPH) gastrointestinal cancer.Type: ApplicationFiled: September 30, 2005Publication date: May 18, 2006Inventors: Seema Garde, Chandra Panchal, Madhulika Baijal-Gupta, Jennifer Fraser, Salam Kadhim
-
Publication number: 20050176672Abstract: A method of generating an anti-tumor immune response using a cationic molecule:biologically active molecule complex is provided. In one embodiment, the anti-tumor immune response is a protective, memory-based response. The complex may be administered alone, as the active ingredient in a formulation, or as an adjuvant. The invention also provides for methods of generating an immunostimulatory response against the tumor cell present during treatment by exposing a cationic molecule:biologically active molecule complex to a mammalian cell or a foreign tumor cell.Type: ApplicationFiled: April 6, 2005Publication date: August 11, 2005Inventors: Ronald Scheule, Nelson Yew, Lee Mizzen, Salam Kadhim
-
Publication number: 20030170220Abstract: The invention provides pharmaceutical compositions and method for inhibiting growth of prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, or benign prostate hyperplasia (BPH). In one embodiment the pharmaceutical composition includes human rHuPSP94, antigenic portions thereof, and functionally equivalent polypeptides thereof. In another embodiment, the pharmaceutical composition includes a mixture of human rHuPSP94, antigenic portions thereof, and functionally equivalent polypeptides thereof and an anticancer drug which may be administered in an appropriate dosage form, dosage quantity and dosage regimen to a patient suffering from, for example of prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, benign prostate hyperplasia, or (BPH) gastrointestinal cancer.Type: ApplicationFiled: October 15, 2001Publication date: September 11, 2003Applicant: PROCYON BIOPHARMA INC.Inventors: Seema Garde, Chandra Panchal, Madhulika Baijal-Gupta, Jennifer Fraser, Salam Kadhim
-
Patent number: 5994361Abstract: The present invention comprises a compound of formula I: ##STR1## R.sub.1 of Formula I is substituted amino represented by formula NR.sup.5 R.sup.6 wherein R.sup.5 and R.sup.6 are independently selected from the group consisting of hydrogen, C.sub.1-4 alkyl, and unsubstituted amino with the proviso that R.sup.5 and R.sup.6 are not both hydrogen, and further that R.sup.5 and R.sup.6 are not both amino. R.sub.2 and R.sub.3 of Formula I are independently selected from the group consisting of hydrogen; C.sub.1-4 alkyl; amino; substituted or unsubstituted thiol; and halogen. Moreover, R.sub.4 of Formula I is represented by the formula R.sup.12 -X.sup.12 wherein R.sup.12 is a saturated or unsaturated linear hydrocarbon chain of 5-20 carbons optionally containing one or more interruptions within the chain by a heteroatom, and optionally substituted with one or more .dbd.O, or .dbd.S. Finally, X.sup.12 is selected from the group consisting of hydroxy, an aminoalkyl group, and a known amino acid bound by its .alpha.Type: GrantFiled: June 7, 1995Date of Patent: November 30, 1999Assignee: Biochem PharmaInventors: Christopher Penney, Boulos Zacharie, Lyne Gagnon, Giorgio Attardo, Timothy P. Connolly, Yves St-Denis, Salam Kadhim